New drug shows promise for fragile x symptoms in small trial
NCT ID NCT06413537
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single dose of SPG601 in 10 adult men with Fragile X syndrome to see if it improves symptoms like attention and behavior. Participants were randomly assigned to receive either the drug or a placebo, and neither they nor their doctors knew which they got. The goal was to measure changes in clinical ratings, caregiver observations, and brain responses to sound.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A common antidepressant may tame anxiety in kids with autism and ADHD — a trial puts it to the test
- Can early parent coaching help infants with rare genetic disorders thrive?
- Experimental drug aims to boost brain function in fragile x syndrome
- Newborn screening study aims to catch rare diseases at birth
- New drug trial aims to ease fragile x symptoms in men
- New study tests medications for brain symptoms in three genetic disorders